News | December 19, 2025
Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The state-of-the-art facility is expected to be commissioned over the next three years
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
This recognition demonstrate excellence in intellectual property (IP) value creation.
Patients with BRCA mutations often face aggressive disease and poor prognosis
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
India plays a critical role in Bristol Myers Squibb’s global strategy
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The company operates a chain of mid-sized multi-speciality hospitals
Subscribe To Our Newsletter & Stay Updated
